• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

    10/1/25 4:30:00 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETNB alert in real time by email

    Basel, 1 October 2025 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ:ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of September 17, 2025, among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc., and 89bio.

    The tender offer period will expire at one minute after 11:59 p.m., New York City time on October 29, 2025, unless the offer is extended.

    Roche has filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (SEC). Bluefin Merger Subsidiary, Inc. is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer.

    89bio has also filed a Solicitation/Recommendation Statement with the SEC on Schedule 14D-9, which includes the unanimous recommendation of the 89bio board of directors that 89bio stockholders tender their shares in the tender offer. The closing of the tender offer is conditioned upon customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and there being validly tendered and not validly withdrawn a majority of the outstanding shares of 89bio common stock. The offer is not subject to any financing condition. Following successful completion of the tender offer, any shares not acquired in the tender offer will be acquired in a second-step merger at the same price of $14.50 per share, plus the CVR. The closing of the transaction is expected to take place in the fourth quarter of 2025.

    The complete terms and conditions are set out in the Offer to Purchase, which was filed with the SEC today, October 1, 2025. 89bio stockholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website (www.sec.gov) or by directing a request for the Solicitation/Recommendation Statement on Schedule 14D-9 to 89bio's website at www.89bio.com or the Offer to Purchase and the other related materials to MacKenzie Partners, Inc., the Information Agent for the offer, toll free at (800) 322-2885 (or please call (212) 929-5500 if you are located outside the U.S. or Canada) or via email at [email protected].

    Before making any decision with respect to the Offer, investors are urged to read the Offer to Purchase and related documents, as well as the Solicitation/Recommendation Statement, because they contain important information about the Offer.

    About 89bio

    89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. 89bio is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com.

    About Roche

    Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

    For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

    Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

    For more information, please visit www.roche.com.

    All trademarks used or mentioned in this release are protected by law.

     

    CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

    This communication may include statements that are not statements of historical fact, or "forward-looking statements," within the meaning of the federal securities laws, including with respect to Roche's proposed acquisition of 89bio. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. These statements are generally identified by words or phrases such as "believe", "anticipate", "expect", "intend", "plan", "will", "may", "should", "estimate", "predict", "project", "strategy", "potential", "continue" or the negative of such terms or other similar expressions. Such statements include, but are not limited to, the ability of Roche and 89bio to complete the transactions contemplated by the merger agreement, including each party's ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement, statements about the expected timetable for completing the transaction, the parties' beliefs and expectations and statements about the benefits sought to be achieved in Roche's proposed acquisition of 89bio, the potential effects of the acquisition on both Roche and 89bio and the possibility of any termination of the merger agreement. These statements are based upon the current beliefs and expectations of Roche and 89bio's management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable, if at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements, and you should not place undue reliance on these statements.

    Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of 89bio's stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the offer and the merger contemplated by the merger agreement may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the tender offer or the subsequent merger; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on 89bio's business; the possibility that the milestones related to the contingent value right will never be achieved and that no milestone payments may be made; and the risk of legal proceedings being brought in relation to the transactions and the outcome of such proceedings, including the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in 89bio's public filings with the SEC, including the "Risk Factors" section of 89bio's Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q, Form 8-K and in other filings 89bio makes with the SEC from time to time as well as the tender offer materials filed by Roche and its acquisition subsidiary and the Solicitation/Recommendation Statement to be filed by 89bio, in each case as amended by any subsequent filings made with the SEC.

    Neither Roche nor 89bio undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.

     

    Roche Global Media Relations

    Phone: +41 61 688 8888 / e-mail: [email protected]

    Hans Trees, PhD

    Phone: +41 79 407 72 58
    Sileia Urech

    Phone: +41 79 935 81 48



     
    Nathalie Altermatt

    Phone: +41 79 771 05 25
    Lorena Corfas

    Phone: +41 79 568 24 95



     
    Simon Goldsborough

    Phone: +44 797 32 72 915
    Karsten Kleine

    Phone: +41 79 461 86 83



     
    Kirti Pandey

    Phone: +49 172 6367262
    Yvette Petillon

    Phone: +41 79 961 92 50



     
    Dr Rebekka Schnell

    Phone: +41 79 205 27 03


     

    Roche Investor Relations

    Dr Bruno Eschli

    Phone: +41 61 68-75284

    e-mail: [email protected]
    Dr Sabine Borngräber

    Phone: +41 61 68-88027

    e-mail: [email protected]



     
    Dr Birgit Masjost

    Phone: +41 61 68-84814

    e-mail: [email protected]
     

    Investor Relations North America

    Loren Kalm

    Phone: +1 650 225 3217

    e-mail: [email protected]

     

    Attachment

    • Media Investor Release 89bio tender offer English


    Primary Logo

    Get the next $ETNB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETNB

    DatePrice TargetRatingAnalyst
    9/4/2025$32.00Buy
    H.C. Wainwright
    3/14/2025$11.00Neutral
    Goldman
    3/13/2025$25.00Buy
    Citigroup
    2/4/2025Outperform
    Wolfe Research
    4/22/2024$30.00Buy
    BofA Securities
    1/12/2024$24.00 → $15.00Outperform → Sector Perform
    RBC Capital Mkts
    10/10/2023Outperform → Perform
    Oppenheimer
    8/28/2023$36.00Buy
    UBS
    More analyst ratings

    $ETNB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

    Basel, 1 October 2025 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ:ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of September 17, 2025, among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc., and 89bio. The tender offer period

    10/1/25 4:30:00 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    89bio, Inc. Announces Agreement to be Acquired by Roche

    – 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion – – Transaction reflects pegozafermin's potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH) – – 89bio to join the Roche Group as part of Roche's Pharmaceuticals Division – SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on th

    9/18/25 1:02:18 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

    89bio's pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesityAcquisition supports Roche's strategy as it enhances the company's portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination developmentRoche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$2.4 billion. Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US$6.00 per share in cash, representing a total deal value of up to appr

    9/18/25 1:00:00 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by 89bio Inc.

    SCHEDULE 13D - 89bio, Inc. (0001785173) (Subject)

    10/3/25 4:01:19 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 14D9 filed by 89bio Inc.

    SC 14D9 - 89bio, Inc. (0001785173) (Subject)

    10/1/25 4:45:15 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-T filed by 89bio Inc.

    SC TO-T - 89bio, Inc. (0001785173) (Subject)

    10/1/25 4:01:57 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Le-Nguyen Quoc covered exercise/tax liability with 8,202 shares, decreasing direct ownership by 2% to 301,684 units (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    8/5/25 8:14:06 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mansbach Harry H covered exercise/tax liability with 7,680 shares, decreasing direct ownership by 2% to 302,656 units (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    8/5/25 8:14:01 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Martins Ryan covered exercise/tax liability with 7,680 shares, decreasing direct ownership by 3% to 253,496 units (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    8/5/25 8:11:05 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on 89bio with a new price target

    H.C. Wainwright resumed coverage of 89bio with a rating of Buy and set a new price target of $32.00

    9/4/25 8:59:48 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on 89bio with a new price target

    Goldman initiated coverage of 89bio with a rating of Neutral and set a new price target of $11.00

    3/14/25 7:36:30 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on 89bio with a new price target

    Citigroup initiated coverage of 89bio with a rating of Buy and set a new price target of $25.00

    3/13/25 7:35:31 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    2/3/25 5:38:09 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mcwherter Charles bought $99,850 worth of shares (15,000 units at $6.66), increasing direct ownership by 150% to 25,000 units (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    1/23/25 7:38:31 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Palekar Rohan bought $39,450 worth of shares (5,000 units at $7.89), increasing direct ownership by 1% to 471,236 units (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    12/10/24 6:02:26 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    Leadership Updates

    Live Leadership Updates

    View All

    89bio, Inc. Announces Agreement to be Acquired by Roche

    – 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion – – Transaction reflects pegozafermin's potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH) – – 89bio to join the Roche Group as part of Roche's Pharmaceuticals Division – SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on th

    9/18/25 1:02:18 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

    SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through

    9/16/24 4:05:00 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    89bio Appoints Francis Sarena as Chief Operating Officer

    SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov

    8/7/24 8:00:00 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    Financials

    Live finance-specific insights

    View All

    89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

    - 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot

    3/22/23 7:00:00 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

    - Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In

    6/28/22 4:01:00 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

    - Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.

    3/1/22 4:03:00 PM ET
    $ETNB
    $NLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 89bio Inc.

    SC 13D/A - 89bio, Inc. (0001785173) (Subject)

    11/18/24 8:19:11 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 89bio Inc.

    SC 13G/A - 89bio, Inc. (0001785173) (Subject)

    11/14/24 4:30:44 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 89bio Inc.

    SC 13G/A - 89bio, Inc. (0001785173) (Subject)

    11/14/24 12:47:48 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care